Patient Forum

The CyberKnife Patient Forum is designed to provide a place for people who have been diagnosed with cancer, their family and friends, to exchange useful information and provide support to one another. The Forum may also help people find answers to questions they have about the CyberKnife treatment experience. Accuray strives to facilitate these exchanges and encourage discussions. Recently we have experienced some aggressive or inappropriate spam postings. We are diligently working to resolve this issue and thank you in advance for your patience.

Birgit Fleurent, Chief Marketing Officer, Accuray Incorporated

A highly selective BCR-ABL tyrosine kinase inhibitor
Posted: Tuesday, April 07, 2015 7:32 PM
Joined: 4/7/2015
Posts: 1

Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold far more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. Within this phase two open-label study, 400 mg nilotinib was administered orally twice day-to-day to 280 individuals with Philadelphia chromosome�Cpositive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) right after imatinib failure or intolerance. Patients had at the least 6 months of follow-up and had been evaluated for hematologic and cytogenetic responses, and also for safety and general survival. At 6 months, the rate of important cytogenetic response (Ph < 35%) was 48%: full (Ph = 0%) in 31%, and partial (Ph = 1%-35%) in 16%. The estimated survival at 12 months was 95%. Nilotinib was powerful in individuals harboring BCR-ABL mutations linked to imatinib resistance (except T315I), as well as in patients having a resistance mechanism independent of BCR-ABL mutations. Adverse events were mostly mild to moderate, and there was minimal cross- intolerance with imatinib. Grades 3 to 4 neutropenia and thrombocytopenia had been observed in 29% of sufferers; pleural or pericardial effusions were observed in 1% (none were serious). In summary, nilotinib is very active and secure in patients with CML-CP following imatinib failure or intolerance. This clinical trial is registered at
inhibitor expert

Jump to different Forum...